Reports Q3 revenue $785M, consensus $773.81M. “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ongoing evolution of our portfolio. CREXONT for Parkinson’s disease and other key branded products continue to drive Specialty growth, complemented by the launch this month of BREKIYA in the migraine space. At the same time, our Affordable Medicines segment is entering a significant new product launch cycle, with multiple complex approvals this quarter and numerous new key launches expected ahead. Together with our recent refinancing, Amneal is closing 2025 and entering 2026 from a position of strength and momentum,” said Chirag and Chintu Patel, Co-CEOs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal gets FDA approval for beclomethasone dipropionate HFA inhalation aerosol
- Mycophenolate Pregnancy Registry: Key Insights for Investors
- Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?
- Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection
- Amneal treatment of known or suspected cyanide poisoning granted orphan status